Lantern Pharma (LTRN) Non-Current Assets (2019 - 2026)

Lantern Pharma (LTRN) has reported Non-Current Assets for 8 consecutive years, with $143430.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 34.66% year-over-year to $143430.0; the trailing twelve-month figure through Jun 2026 stood at $707681.0 (down 40.48% YoY), and the FY2025 full-year result was $232639.0, down 28.23% from the prior year.
• Non-Current Assets fell to $143430.0 in Q2 2026 per LTRN's latest filing, from $165807.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $739359.0 in Q1 2022 and bottomed at $113584.0 in Q4 2022.
• Historically, Non-Current Assets has averaged $308186.2 across 5 years, with a median of $284155.5 in 2024.
• The widest YoY moves for Non-Current Assets: up 3566.73% in 2022, down 90.8% in 2022.
• Over 5 years, Non-Current Assets stood at $113584.0 in 2022, then jumped by 169.66% to $306291.0 in 2023, then climbed by 5.83% to $324163.0 in 2024, then declined by 28.23% to $232639.0 in 2025, then sank by 38.35% to $143430.0 in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $143430.0, $165807.0, and $232639.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.